CN102292341B - 对apo a有活性的噻吩并三唑并二氮杂*衍生物 - Google Patents

对apo a有活性的噻吩并三唑并二氮杂*衍生物 Download PDF

Info

Publication number
CN102292341B
CN102292341B CN200980150891.6A CN200980150891A CN102292341B CN 102292341 B CN102292341 B CN 102292341B CN 200980150891 A CN200980150891 A CN 200980150891A CN 102292341 B CN102292341 B CN 102292341B
Authority
CN
China
Prior art keywords
compound
formula
och
hydrogen
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980150891.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102292341A (zh
Inventor
H·柯莫潘
D·比鲁斯
B·斯蒂赫林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DYBLY AG
Original Assignee
DYBLY AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DYBLY AG filed Critical DYBLY AG
Publication of CN102292341A publication Critical patent/CN102292341A/zh
Application granted granted Critical
Publication of CN102292341B publication Critical patent/CN102292341B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN200980150891.6A 2008-10-30 2009-10-29 对apo a有活性的噻吩并三唑并二氮杂*衍生物 Expired - Fee Related CN102292341B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08167982 2008-10-30
EP08167982.1 2008-10-30
PCT/EP2009/064243 WO2010049466A1 (en) 2008-10-30 2009-10-29 Thienotriazolodiazepine derivatives active on apo a

Publications (2)

Publication Number Publication Date
CN102292341A CN102292341A (zh) 2011-12-21
CN102292341B true CN102292341B (zh) 2014-09-10

Family

ID=40380148

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980150891.6A Expired - Fee Related CN102292341B (zh) 2008-10-30 2009-10-29 对apo a有活性的噻吩并三唑并二氮杂*衍生物

Country Status (11)

Country Link
US (1) US8569288B2 (2)
EP (1) EP2362876B1 (2)
JP (1) JP5490811B2 (2)
KR (1) KR101633742B1 (2)
CN (1) CN102292341B (2)
AU (1) AU2009309691B2 (2)
BR (1) BRPI0914406A2 (2)
CA (1) CA2741934C (2)
EA (1) EA018620B1 (2)
ES (1) ES2448567T3 (2)
WO (1) WO2010049466A1 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
EP2571875A4 (en) 2010-05-14 2013-10-30 Dana Farber Cancer Inst Inc CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF
CN103119160B (zh) * 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
US9975896B2 (en) 2013-07-25 2018-05-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
JP2017506666A (ja) 2014-02-28 2017-03-09 テンシャ セラピューティクス，インコーポレイテッド 高インスリン血症に関連した症状の処置
PL3157928T3 (pl) 2014-06-20 2019-07-31 Constellation Pharmaceuticals, Inc. Krystaliczne postacie 2-((4S)-6-(4-chlorofenylo)-1-metylo-4H-benzo[ c]izoksazolo-[4,5-e]azepin-4-ylo)acetamidu
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
CN106793775B (zh) 2014-08-08 2020-06-02 达纳-法伯癌症研究所股份有限公司 二氢碟啶酮衍生物及其用途
KR20170068597A (ko) 2014-10-27 2017-06-19 텐샤 세러퓨틱스 인코포레이티드 브로모도메인 저해제
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
EP3347021A4 (en) 2015-09-11 2019-07-24 Dana-Farber Cancer Institute, Inc. CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
MX2018006499A (es) * 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
AU2019284971A1 (en) 2018-06-13 2020-12-03 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Preparation of condensed triazepine derivatives and their use as BET inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
US4621083A (en) * 1984-10-01 1986-11-04 Boehringer Ingelheim Kg PAF-antagonistic diazepines
US4960770A (en) * 1987-05-28 1990-10-02 Yoshitomi Pharmaceutical Industries, Ltd. 2-alkyl thieno(triazolo)diazepine compounds and pharmaceutical uses thereof
CN1195989A (zh) * 1995-09-09 1998-10-14 弗·哈夫曼-拉罗切有限公司 噻吩并三唑并二氮杂䓬增加载脂蛋白a－i含量的用途
US6444664B1 (en) * 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
US4621083A (en) * 1984-10-01 1986-11-04 Boehringer Ingelheim Kg PAF-antagonistic diazepines
US4960770A (en) * 1987-05-28 1990-10-02 Yoshitomi Pharmaceutical Industries, Ltd. 2-alkyl thieno(triazolo)diazepine compounds and pharmaceutical uses thereof
CN1195989A (zh) * 1995-09-09 1998-10-14 弗·哈夫曼-拉罗切有限公司 噻吩并三唑并二氮杂䓬增加载脂蛋白a－i含量的用途
US6444664B1 (en) * 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease;A Merched，等;《Neurobiology of Aging》;20000229;第21卷(第1期);第27-30页，参见第27页摘要 *

Also Published As

Publication number Publication date
US8569288B2 (en) 2013-10-29
KR20110091523A (ko) 2011-08-11
JP5490811B2 (ja) 2014-05-14
ES2448567T3 (es) 2014-03-14
AU2009309691A1 (en) 2010-05-06
CA2741934C (en) 2016-09-13
US20110230460A1 (en) 2011-09-22
EP2362876B1 (en) 2013-12-11
EP2362876A1 (en) 2011-09-07
KR101633742B1 (ko) 2016-06-27
EA201100698A1 (ru) 2011-12-30
JP2012506896A (ja) 2012-03-22
WO2010049466A1 (en) 2010-05-06
CN102292341A (zh) 2011-12-21
AU2009309691B2 (en) 2015-04-02
EA018620B1 (ru) 2013-09-30
BRPI0914406A2 (pt) 2015-10-20
CA2741934A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
CN102292341B (zh) 对apo a有活性的噻吩并三唑并二氮杂*衍生物
US8158792B2 (en) Spiropiperidines for use as tryptase inhibitors
CN102712645B (zh) 化合物
JP6896113B2 (ja) ジアザ二環式置換イミダゾピリミジンおよび呼吸障害を治療するためのその使用
JPWO1993007129A1 (ja) 骨粗鬆症治療薬およびジアゼピン化合物
TWI419889B (zh) 吡唑并〔１，５-ａ〕嘧啶化合物
CN1964973A (zh) 吡唑并嘧啶衍生物
US20100261711A1 (en) Selective anticonvulsant agents and their uses
JP2005525392A (ja) 減少された鎮静及び失調効果を有する抗不安薬剤
KR20130083389A (ko) 야누스 키나아제 억제제로서 헤테로사이클릭 화합물
CN103443076B (zh) 在3位双取代的吲哚-2-酮衍生物、其制备和其治疗应用
JPH0565288A (ja) 新規なアシルアミノ置換ヘトラゼピン誘導体、その製法及びそれを含有する医薬組成物
TW200808779A (en) Novel compound
NZ540768A (en) Benzamide derivatives as oxytocin agonists and vasopressin antagonists
JPWO1997000258A1 (ja) 三環性ベンゾアゼピン化合物
WO2025139240A1 (zh) Parp7抑制剂及其用途
EA005071B1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[4,3-e]ДИАЗЕПИНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ ПРОДУКТОВ
WO2026010962A1 (en) 3-pyrrolidine-indole derivative compounds useful for the treatment of disorders and methods related thereto
KR101459720B1 (ko) 세로토닌 5-ＨＴ6 저해 활성을 갖는 5-설포닐아미노-5,6-다이하이드로-1Ｈ-피라졸로[3,4-ｃ]피리딘-7(4Ｈ)-온 화합물
HK1192230B (en) Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
WO2006084835A1 (en) N-(3-(imidazo [1,5-a]pyrimidin-4-yl)phenyl]-sulfonamides and n-[3-(imidazo[1,5-a]pyrimidin-4-yl)-phenyl]-carboxamides and their use as gabaa receptor modulators
TW200911234A (en) Compounds which inhibit the glycine transporter and uses thereof in medicine
HK1105971B (en) Pyrrazolo-pyrimidine derivatives
HK1192230A (en) Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140910

Termination date: 20181029